DraftKings (DKNG): Examining Valuation After Recent Volatility and Momentum in the Stock

If you have been tracking DraftKings (DKNG), you may have noticed the stock’s recent movement and are likely wondering what is next. While there is no clear event driving the action right now, the current volatility still raises interesting questions for anyone considering a position. Sometimes, it is moves without direct catalysts that signal shifts in market sentiment or present valuation mismatches worth a closer look.

Looking at the bigger picture, DraftKings has seen its share price climb roughly 28% over the past year, with gains accelerating in the past 3 months. Short-term momentum appears to be building again after a modest pullback last week. These swings come amid ongoing revenue growth and, notably, a substantial improvement in net income. These factors continue to shape expectations for the company’s path toward profitability.

So, after a year of sharp gains and a strong fundamental backdrop, is DraftKings trading at a discount to fair value, or is the market already pricing in the next wave of growth?

Advertisement

Most Popular Narrative: 15.6% Undervalued

According to the most widely followed narrative, DraftKings is currently trading at a discount to its intrinsic value, with a fair value estimate higher than the prevailing market price. This suggests that analysts see fundamental upside not yet reflected in the current share price.

DraftKings' proprietary technology, enhanced by the acquisition of Simplebet and in-house developments, is enabling unique betting formats and vertical integration. This is expected to support higher gross margins and strengthen competitive positioning, positively impacting long-term earnings and operating leverage.

Curious what helps DraftKings stand apart in the rapidly evolving world of online betting? Underneath this valuation lies a powerful bet on future growth, expanding margins, and strategic tech moves that could shake up the industry. Want to know which financial assumptions are driving these bullish targets? The details may surprise you. Discover what’s fueling this enthusiastic outlook.

Result: Fair Value of $54.86 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, DraftKings faces mounting regulatory risk and rising state-level tax policies. These factors could challenge the optimistic outlook if conditions worsen.

Find out about the key risks to this DraftKings narrative.

Another View: Looking at the Market Multiple

While some see DraftKings as undervalued based on future cash flows, comparing its price-to-sales against the industry average suggests the opposite. Could market enthusiasm be pushing shares ahead of what fundamentals support?

See what the numbers say about this price — find out in our valuation breakdown.
NasdaqGS:DKNG PS Ratio as at Sep 2025
NasdaqGS:DKNG PS Ratio as at Sep 2025
Stay updated when valuation signals shift by adding DraftKings to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own DraftKings Narrative

If you see things differently or want to dive into your own research, it is quick and easy to build your own valuation story. Do it your way

A great starting point for your DraftKings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for Your Next Winning Stock?

Why limit your portfolio to just one contender? Use the Simply Wall Street Screener to uncover standout stocks and fresh opportunities that fit your unique investment strategy.

  • Tap into untapped growth by checking out penny stocks with strong financials through penny stocks with strong financials, and spot companies often overlooked by the market.
  • Supercharge your watchlist with the latest AI breakthroughs by searching for AI penny stocks, and get ahead in the fast-evolving world of artificial intelligence.
  • Secure greater value for your money by finding undervalued stocks based on cash flows using fundamental analysis to highlight promising investments that may be trading below their true worth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Kshitija Bhandaru

Kshitija Bhandaru

Kshitija (or Keisha) Bhandaru is an Equity Analyst at Simply Wall St and has over 6 years of experience in the finance industry and describes herself as a lifelong learner driven by her intellectual curiosity. She previously worked with Market Realist for 5 years as an Equity Analyst.

About NasdaqGS:DKNG

DraftKings

Operates as a digital sports entertainment and gaming company in the United States and internationally.

Good value with reasonable growth potential.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
66 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
22 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0